Updated on 27 October 2026
AI-Driven Analytics & Digital Tools for Health Innovation (Coremine Vitae, Norway)
Chief Executive Officer at Coremine Vitae
Oslo, Norway
About
Coremine Vitae is a Norwegian SME specialising in trustworthy, explainable AI, evidence synthesis, and data integration that turn complex health information into clear, decision-ready insights. We work in high-complexity biomedical and precision-medicine settings, building reproducible pipelines and user-facing tools that support better decisions under uncertainty.
For Cluster 1 Health projects, we contribute the AI/data backbone that helps consortia move from fragmented data and literature to actionable outputs—while ensuring transparency, traceability, and usability for clinical and R&D stakeholders.
What we can contribute
-
Data integration pipelines combining clinical data, molecular data (e.g., multi-omics), and literature into structured, traceable workflows
-
Explainable analytics with interpretable models and robust documentation to support trust and uptake
-
Decision-support outputs (dashboards, structured reports, evidence summaries) for clinicians, researchers, and innovation teams
-
Evaluation & quality practices (validation support, traceability, responsible AI considerations)
Partner interest
We seek partners across academia, hospitals/clinical centres, patient organisations, SMEs/industry, and public stakeholders. We typically join as a technical partner, enabling implementation and validation by clinical and domain-leading partners.
Attached files
Organisation
Similar opportunities
Project cooperation
AI, Bioinformatics and Digital Twins for Personalised Medicine and Digital Health
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Maria Mastrangelopoulou, MSc, PhD
Chief Executive Officer at Coremine Vitae
Oslo, Norway
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Miguel Ángel Armengol de la Hoz
Head of Data Science Lab | Progress and Health Foundation (FPS) | Andalusian Ministry of Health at Data Science Lab (LCD) – Progress and Health Foundation (FPS)
Sevilla, Spain
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Abdulkadir Kayıklı
Founder at Finakis
Istanbul, Türkiye